149 related articles for article (PubMed ID: 38287511)
121. Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7-Expressing Carcinoma in the Cervicovaginal Tract.
Henkle TR; Lam B; Kung YJ; Lin J; Tseng SH; Ferrall L; Xing D; Hung CF; Wu TC
Cancer Res; 2021 Sep; 81(17):4560-4569. PubMed ID: 34215618
[TBL] [Abstract][Full Text] [Related]
122. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
123. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.
Kim SS; Shen S; Miyauchi S; Sanders PD; Franiak-Pietryga I; Mell L; Gutkind JS; Cohen EEW; Califano JA; Sharabi AB
Clin Cancer Res; 2020 Jul; 26(13):3345-3359. PubMed ID: 32193227
[TBL] [Abstract][Full Text] [Related]
124. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy.
Pal A; Kundu R
Front Microbiol; 2019; 10():3116. PubMed ID: 32038557
[TBL] [Abstract][Full Text] [Related]
125. HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory.
Grunwitz C; Salomon N; Vascotto F; Selmi A; Bukur T; Diken M; Kreiter S; Türeci Ö; Sahin U
Oncoimmunology; 2019; 8(9):e1629259. PubMed ID: 31428528
[TBL] [Abstract][Full Text] [Related]
126. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
[TBL] [Abstract][Full Text] [Related]
127. HPV vaccines: Global perspectives.
Gupta G; Glueck R; Patel PR
Hum Vaccin Immunother; 2017 Jun; 13(6):1-4. PubMed ID: 28362244
[TBL] [Abstract][Full Text] [Related]
128. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.
Wood O; Woo J; Seumois G; Savelyeva N; McCann KJ; Singh D; Jones T; Peel L; Breen MS; Ward M; Garrido Martin E; Sanchez-Elsner T; Thomas G; Vijayanand P; Woelk CH; King E; Ottensmeier C;
Oncotarget; 2016 Aug; 7(35):56781-56797. PubMed ID: 27462861
[TBL] [Abstract][Full Text] [Related]
129. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
130. Human papillomavirus molecular biology and disease association.
Doorbar J; Egawa N; Griffin H; Kranjec C; Murakami I
Rev Med Virol; 2015 Mar; 25 Suppl 1(Suppl Suppl 1):2-23. PubMed ID: 25752814
[TBL] [Abstract][Full Text] [Related]
131. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.
Chatterjee A
Expert Rev Vaccines; 2014 Nov; 13(11):1279-90. PubMed ID: 25256262
[TBL] [Abstract][Full Text] [Related]
132. Human papillomavirus oncoproteins: pathways to transformation.
Moody CA; Laimins LA
Nat Rev Cancer; 2010 Aug; 10(8):550-60. PubMed ID: 20592731
[TBL] [Abstract][Full Text] [Related]
133. All 4 di-leucine motifs in the first hydrophobic domain of the E5 oncoprotein of human papillomavirus type 16 are essential for surface MHC class I downregulation activity and E5 endomembrane localization.
Cortese MS; Ashrafi GH; Campo MS
Int J Cancer; 2010 Apr; 126(7):1675-82. PubMed ID: 19876920
[TBL] [Abstract][Full Text] [Related]
134. Immunoinformatics: current trends and future directions.
Tong JC; Ren EC
Drug Discov Today; 2009 Jul; 14(13-14):684-9. PubMed ID: 19379830
[TBL] [Abstract][Full Text] [Related]
135. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
[TBL] [Abstract][Full Text] [Related]
136. Papillomaviruses and cancer: from basic studies to clinical application.
zur Hausen H
Nat Rev Cancer; 2002 May; 2(5):342-50. PubMed ID: 12044010
[TBL] [Abstract][Full Text] [Related]
137. Mechanisms of cell transformation by papillomavirus E5 proteins.
DiMaio D; Mattoon D
Oncogene; 2001 Nov; 20(54):7866-73. PubMed ID: 11753669
[TBL] [Abstract][Full Text] [Related]
138. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
Walboomers JM; Jacobs MV; Manos MM; Bosch FX; Kummer JA; Shah KV; Snijders PJ; Peto J; Meijer CJ; Muñoz N
J Pathol; 1999 Sep; 189(1):12-9. PubMed ID: 10451482
[TBL] [Abstract][Full Text] [Related]
139. Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice.
Gulliver GA; Herber RL; Liem A; Lambert PF
J Virol; 1997 Aug; 71(8):5905-14. PubMed ID: 9223480
[TBL] [Abstract][Full Text] [Related]
140. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.
Dyson N; Howley PM; Münger K; Harlow E
Science; 1989 Feb; 243(4893):934-7. PubMed ID: 2537532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
